Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mills

Showing results (1221-1230 of 1,298) with videos related to

Pageof 130
Sort By:
The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Cancer Discovery|April 27, 2013
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkersVivian W Y Lui, Matthew L Hedberg, Hua Li, et al.
Nature Communications|May 30, 2014
A pan-cancer proteomic perspective on The Cancer Genome AtlasRehan Akbani, Patrick Kwok Shing Ng, Henrica M J Werner, et al.
Science Translational Medicine|January 10, 2024
mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduriaSonam Gurung, Oskar Vilhelmsson Timmermand, Dany Perocheau, et al.
Cancer Discovery|September 14, 2017
A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling RolesVito W Rebecca, Michael C Nicastri, Noel McLaughlin, et al.
Oncogene|December 16, 2020
Hormonal modulation of ESR1 mutant metastasisGuowei Gu, Lin Tian, Sarah K Herzog, et al.
BMC Medicine|October 26, 2016
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setJason Roszik, Lauren E Haydu, Kenneth R Hess, et al.
Cancer Cell|December 10, 2014
Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancersPradeep Chaluvally-Raghavan, Fan Zhang, Sunila Pradeep, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2019
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome ConsortiumB T Li, F Janku, B Jung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced CancerFilip Janku, Shile Zhang, Jill Waters, et al.
Pageof 130

Showing results (1221-1230 of 1,298) with videos related to

Sort By:
Pageof 130
The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Cancer Discovery|April 27, 2013
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkersVivian W Y Lui, Matthew L Hedberg, Hua Li, et al.
Nature Communications|May 30, 2014
A pan-cancer proteomic perspective on The Cancer Genome AtlasRehan Akbani, Patrick Kwok Shing Ng, Henrica M J Werner, et al.
Science Translational Medicine|January 10, 2024
mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduriaSonam Gurung, Oskar Vilhelmsson Timmermand, Dany Perocheau, et al.
Cancer Discovery|September 14, 2017
A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling RolesVito W Rebecca, Michael C Nicastri, Noel McLaughlin, et al.
Oncogene|December 16, 2020
Hormonal modulation of ESR1 mutant metastasisGuowei Gu, Lin Tian, Sarah K Herzog, et al.
BMC Medicine|October 26, 2016
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setJason Roszik, Lauren E Haydu, Kenneth R Hess, et al.
Cancer Cell|December 10, 2014
Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancersPradeep Chaluvally-Raghavan, Fan Zhang, Sunila Pradeep, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2019
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome ConsortiumB T Li, F Janku, B Jung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced CancerFilip Janku, Shile Zhang, Jill Waters, et al.
Pageof 130